These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 34918213)

  • 21. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
    Nguyen H; Dufour R; Caldwell-Tarr A
    Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.
    Divino V; Boye KS; Lebrec J; DeKoven M; Norrbacka K
    Diabetes Ther; 2019 Jun; 10(3):1067-1088. PubMed ID: 31028689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin.
    Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
    Diabetes Ther; 2018 Jun; 9(3):1233-1251. PubMed ID: 29713961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin.
    Blonde L; Raccah D; Lew E; Meyers J; Nikonova E; Ajmera M; Davis KL; Bertolini M; Guerci B
    Diabetes Ther; 2018 Jun; 9(3):1169-1184. PubMed ID: 29675797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States.
    Weiss T; Carr RD; Pal S; Yang L; Sawhney B; Boggs R; Rajpathak S; Iglay K
    Patient Prefer Adherence; 2020; 14():2337-2345. PubMed ID: 33273810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
    Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
    Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
    Cai J; Divino V; Burudpakdee C
    Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.
    Divino V; DeKoven M; Khan FA; Boye KS; Sapin H; Norrbacka K
    Diabetes Ther; 2017 Feb; 8(1):115-128. PubMed ID: 28070733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of medication persistence and adherence in type 2 diabetes using a once-weekly regimen of DPP-4 inhibitor compared with once-daily and twice-daily regimens: a retrospective cohort study of Japanese health insurance claims data.
    Miwa T; Yoshida S; Nakajima A; Koto R; Nishimura R
    Diabetol Int; 2024 Jul; 15(3):483-494. PubMed ID: 39101196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.
    Gleason PP; Urick BY; Marshall LZ; Friedlander N; Qiu Y; Leslie RS
    J Manag Care Spec Pharm; 2024 Aug; 30(8):860-867. PubMed ID: 38717042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.
    Wang K; Chen Y; Strizek A; Boye K; Gu L; Liu Y; Qu S
    Clin Ther; 2019 Oct; 41(10):2057-2065. PubMed ID: 31514971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes.
    Palanca A; Ampudia-Blasco FJ; Calderón JM; Sauri I; Martinez-Hervás S; Trillo JL; Redón J; Real JT
    Diabetes Ther; 2023 Apr; 14(4):723-736. PubMed ID: 36847952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis.
    Hersh CM; Gorritz M; Chen CC; Tuly R; Gu Y; Gadkari A; Brown B; Shao Q
    Mult Scler Relat Disord; 2024 Nov; 91():105888. PubMed ID: 39388747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK.
    Weiss T; Yang L; Carr RD; Pal S; Sawhney B; Boggs R; Rajpathak S; Iglay K
    BMJ Open Diabetes Res Care; 2022 Jan; 10(1):. PubMed ID: 35101924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment.
    Mody R; Grabner M; Yu M; Turner R; Kwan AYM; York W; Fernández Landó L
    Curr Med Res Opin; 2018 Jun; 34(6):995-1003. PubMed ID: 29271258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in US Adults with Type 2 Diabetes.
    Tan X; Liang Y; Gamble C; King A
    Diabetes Ther; 2024 Feb; 15(2):427-445. PubMed ID: 38060149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.
    Blauvelt A; Burge R; Gallo G; Charbonneau B; Malatestinic W; Zhu B; Wan F; Lockshin B
    Dermatol Ther (Heidelb); 2022 Mar; 12(3):701-714. PubMed ID: 35220545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Patel D
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.
    Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
    Diabetes Ther; 2018 Jun; 9(3):1149-1167. PubMed ID: 29675798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
    García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H
    Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.